AZN - AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer | Benzinga
AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the first quarter of 2024.
Each year, an estimated 2.2 million people are diagnosed with lung ...